By signing up and joining our community of healthcare providers, you’ll receive relevant updates to keep you informed
From the latest research to patient resources, we’re here to provide you with the tools you need to help treat the inflammatory lesions of rosacea
There is one final step before you can gain access to this resource
By providing us with your details, we will let you know when relevant information on your chosen interests becomes available
For more information on how ORACEA Capsules can safely and
effectively treat your rosacea patients, return to our website1–3
Indication: ORACEA® (doxycycline) 40 mg* capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA does not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in subjects treated with ORACEA were nasopharyngitis, diarrhea, hypertension and sinusitis. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years) and may cause reversible inhibition of bone growth. If Clostridium difficile associated diarrhea (CDAD) occurs, may need to discontinue ORACEA. Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.
*30 mg immediate release and 10 mg delayed release beads